Last reviewed · How we verify

Naropine — Competitive Intelligence Brief

Naropine (Naropine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain.

phase 1 Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha Pain Small molecule Live · refreshed every 30 min

Target snapshot

Naropine (Naropine) — Rigshospitalet, Denmark.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Naropine TARGET Naropine Rigshospitalet, Denmark phase 1 Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Ropivacain Ropivacain University Hospital, Basel, Switzerland marketed Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Naropeine Naropeine University Hospital, Rouen phase 3 Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naropine — Competitive Intelligence Brief. https://druglandscape.com/ci/naropine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing